Our genomic analysis showed copy number disruption of FGFR1/2 across the cell lines; a result reflected in our human UPS tumour datasets where FGFR1 was CN altered in 60% of cases and FGFR2 in 50%. This evidence concerns the gene FGFR1 and neoplasm.